Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.58 |
| ▸ | CNR1 | P21554 | 8/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2187138 | 0.99 | CNR2 (0.57) | CNR2CNR1TDP1 | |
| SCHEMBL2186060 | 0.93 | CNR1 (0.58) | CNR2CNR1TDP1 | |
| SCHEMBL2187831 | 0.93 | CNR2 (0.54) | CNR2CNR1TDP1 | |
| SCHEMBL2186076 | 0.89 | CNR2 (0.74) | CNR2CNR1TDP1 | |
| SCHEMBL2186048 | 0.88 | CNR2 (0.73) | CNR2CNR1TDP1 | |
| SCHEMBL2187202 | 0.83 | CNR2 (0.73) | CNR2CNR1TDP1 | |
| SCHEMBL2186051 | 0.83 | CNR2 (0.68) | CNR2CNR1TDP1 | |
| SCHEMBL14746889 | 0.82 | CNR2 (0.69) | CNR2CNR1TDP1 | |
| SCHEMBL2186833 | 0.82 | CNR2 (0.72) | CNR2CNR1TDP1 | |
| SCHEMBL2186114 | 0.82 | CNR2 (0.42) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030345-B2 | Tricyclic pyrazole derivatives as cannabinoid receptor modulators | CADILA HEALTHCARE LIMITED (IN) | 2011-10-04 | — | — | US | claimed |
| EP-2343302-A1 | TRICYCLIC PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CADILA HEALTHCARE LIMITED (IN) | 2011-07-13 | — | — | EP | claimed |
| US-20100273791-A1 | TRICYCLIC PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CADILA HEALTHCARE LIMITED | 2010-10-28 | — | — | US | claimed |
| US-8030345-B2 | Tricyclic pyrazole derivatives as cannabinoid receptor modulators | CADILA HEALTHCARE LIMITED (IN) | 2011-10-04 | — | — | US | disclosed |
| EP-2343302-A1 | TRICYCLIC PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CADILA HEALTHCARE LIMITED (IN) | 2011-07-13 | — | — | EP | disclosed |
| US-20100273791-A1 | TRICYCLIC PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CADILA HEALTHCARE LIMITED | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273791-A1 | TRICYCLIC PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, GPR55 | CNR2 1/4885CNR1 2/4885TDP1 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.